<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77249">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01917045</url>
  </required_header>
  <id_info>
    <org_study_id>LSOPCA-021</org_study_id>
    <nct_id>NCT01917045</nct_id>
  </id_info>
  <brief_title>Different Lipid Soluble Opioids for Gynecologic Laparoscopic Surgery Postoperative Patient-controlled Analgesia</brief_title>
  <official_title>Different Lipid Soluble Opioids for Gynecologic Laparoscopic Surgery Postoperative Patient-controlled Analgesia --- a Double Blind Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators noticed that Body Fat Ratio might have great influence on the efficacy of
      different lipid soluble anesthetics. The objective of this clinical trial was to compare
      the effect of  that Body Fat Ratio on the efficacy of different lipid soluble anesthetics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this clinical trial was to compare  the effect of  that Body Fat Ratio on
      the efficacy of different lipid soluble anesthetics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>visual analogue pain scores</measure>
    <time_frame>24hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>we evaluate visual analogue pain scores at different time points within 24 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>nausea &amp; vomiting</measure>
    <time_frame>24hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>we evaluate nausea &amp; vomiting at different time points within 24 hours after surgery. we ask the patient if she feel nausea or/and occured vomit, if so, 1 time will be recorded in the time point for incidence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Post Operative Pain Management</condition>
  <arm_group>
    <arm_group_label>low  body fat percentage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>body fat percentage  less than 30%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>heigh body fat percentage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>body fat percentage more than 30%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil (R30730, brand name Sufenta)</intervention_name>
    <description>sufentanil 1ug/ml</description>
    <arm_group_label>low  body fat percentage</arm_group_label>
    <arm_group_label>heigh body fat percentage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil (R30730, brand name Sufenta) + Morphine</intervention_name>
    <description>sufentanil 0.5ug/ml+morphine 0.25mg/ml</description>
    <arm_group_label>low  body fat percentage</arm_group_label>
    <arm_group_label>heigh body fat percentage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>morphine 0. 5mg/ml</description>
    <arm_group_label>low  body fat percentage</arm_group_label>
    <arm_group_label>heigh body fat percentage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists grade I-II

          -  adults aged over 20 and below 50 years old,

          -  non-smoker,

          -  with normal hepatic and renal function.

        Exclusion Criteria:

          -  smoker ,

          -  any kind of mental disorder or

          -  history use of analgesics for more than 10 consecutive days,

          -  asthma; and

          -  those with digestion tract disorder who would get nausea or vomiting much more easily
             than normal people.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhou yan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PKU 1st hospital</affiliation>
  </overall_official>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 3, 2013</lastchanged_date>
  <firstreceived_date>June 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>ZhouYan</investigator_full_name>
    <investigator_title>M.D</investigator_title>
  </responsible_party>
  <keyword>sufentanil</keyword>
  <keyword>morphine</keyword>
  <keyword>postoperative pain control</keyword>
  <keyword>body fat percentage</keyword>
  <keyword>gynecology laparoscopic surgery</keyword>
  <keyword>lipid solubility</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
